随着个性化医疗（PM）的发展趋势，药物遗传学和药物基因组学（PGx）的应用变得越来越重要。出于临床试验的目的，PGx 的纳入是一种额外的工具，应考虑提高我们对新药有效性和安全性的了解。在 ClinicalTrials.gov 上搜索了包含药物遗传学和 PGx 信息的可用临床试验。结果显示，自 2000 年代以来，包含 PGx 信息的试验数量有所增加，特别是在肿瘤学 (28.43%) 和心理健康 (10.66%) 领域。大多数临床试验都以治疗为主要目的。在那些详细考虑研究的特定基因的临床试验条目中，最常探索的基因是 CYP2D6（特别是在心理健康和疼痛中）、CYP2C9（在血液学中）、CYP2C19（在心脏病学和心理健康中）以及 ABCB1 和 CYP3A5（在移植和心脏病学方面尤其突出）等。研究人员和临床医生应接受药物遗传学和 PGx 方面的培训，以便能够正确解释这些数据，有助于更好的处方决策和改善患者护理，从而提高 PM 的性能。版权所有 © 2023 Nogueiras -阿尔瓦雷斯。

With the trend towards promoting personalised medicine (PM), the application of pharmacogenetics and pharmacogenomics (PGx) is of growing importance. For the purposes of clinical trials, the inclusion of PGx is an additional tool that should be considered for improving our knowledge about the effectiveness and safety of new drugs. A search of available clinical trials containing pharmacogenetic and PGx information was conducted on ClinicalTrials.gov. The results show there has been an increase in the number of trials containing PGx information since the 2000 s, with particular relevance in the areas of Oncology (28.43%) and Mental Health (10.66%). Most of the clinical trials focus on treatment as their primary purpose. In those clinical trials entries where the specific genes considered for study are detailed, the most frequently explored genes are CYP2D6 (especially in Mental Health and Pain), CYP2C9 (in Hematology), CYP2C19 (in Cardiology and Mental Health) and ABCB1 and CYP3A5 (particularly prominent in Transplantation and Cardiology), among others. Researchers and clinicans should be trained in pharmacogenetics and PGx in order to be able to make a proper interpretation of this data, contributing to better prescribing decisions and an improvement in patients' care, which would lead to the performance of PM.Copyright © 2023 Nogueiras-Álvarez.